{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"medRxiv"}],"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T12:35:37Z","timestamp":1768566937355,"version":"3.49.0"},"posted":{"date-parts":[[2023,8,17]]},"group-title":"Neurology","reference-count":61,"publisher":"openRxiv","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2023,8,16]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                <jats:p>\n                  Autopsy studies have demonstrated that comorbid neurodegenerative and cerebrovascular disease occur in the great majority of subjects with Alzheimer disease dementia (ADD), and are likely to additively alter the rate of decline or severity of cognitive impairment. The most important of these are Lewy body disease (LBD), TDP-43 proteinopathy and cerebrovascular disease, including white matter rarefaction (WMR) and cerebral infarcts. Comorbidities may interfere with ADD therapeutic trials evaluation of ADD clinical trials as they may not respond to AD-specific molecular therapeutics. It is possible, however, that at least some comorbidities may be, to some degree, secondary consequences of AD pathology, and if this were true then effective AD-specific therapeutics might also reduce the extent or severity of comorbid pathology. Comorbidities in ADD caused by autosomal dominant mutations such as those in the presenilin-1 (\n                  <jats:italic>PSEN1<\/jats:italic>\n                  ) gene may provide an advantageous perspective on their pathogenesis, and deserve attention because these subjects are increasingly being entered into clinical trials. As ADD associated with\n                  <jats:italic>PSEN1<\/jats:italic>\n                  mutations has a presumed single-cause etiology, and the average age at death is under 60, any comorbidities in this setting may be considered as at least partially secondary to the causative AD mechanisms rather than aging, and thus indicate whether effective ADD therapeutics may also be effective for comorbidities. In this study, we sought to compare the rates and types of ADD comorbidities between subjects with early-onset sporadic ADD (EOSADD; subjects dying under age 60) versus ADD associated with different types of\n                  <jats:italic>PSEN1<\/jats:italic>\n                  mutations, the most common cause of early-onset autosomal dominant ADD. In particular, we were able to ascertain, for the first time, the prevalences of a fairly complete set of ADD comorbidities in United States (US)\n                  <jats:italic>PSEN1<\/jats:italic>\n                  cases as well as the Colombian E280A\n                  <jats:italic>PSEN1<\/jats:italic>\n                  kindred. Data for EOSADD and US\n                  <jats:italic>PSEN1<\/jats:italic>\n                  subjects (with multiple different mutation types) was obtained from the National Alzheimer Coordinating Center (NACC). Colombian cases all had the E280A mutation and had a set of neuropathological observations classified, like the US cases according to the NACC NP10 definitions. Confirmatory of earlier reports, NACC-defined Alzheimer Disease Neuropathological Changes (ADNC) were consistently very severe in early-onset cases, whether sporadic or in\n                  <jats:italic>PSEN1<\/jats:italic>\n                  cases, but were slightly less severe in EOSADD. Amyloid angiopathy was the only AD-associated pathology type with widely-differing severity scores between the 3 groups, with median scores of 3, 2 and 1 in the\n                  <jats:italic>PSEN1<\/jats:italic>\n                  Colombia,\n                  <jats:italic>PSEN1<\/jats:italic>\n                  US and EOSADD cases, respectively. Apoliprotein E genotype did not show significant proportional group differences for the possession of an E-4 or E-2 allele. Of ADD comorbidities, LBD was most common, being present in more than half of all cases in all 3 groups. For TDP-43 co-pathology, the Colombian\n                  <jats:italic>PSEN1<\/jats:italic>\n                  group was the most affected, at about 27%, vs 16% and 11% for the US\n                  <jats:italic>PSEN1<\/jats:italic>\n                  and sporadic US cases, respectively. Notably, hippocampal sclerosis and non-AD tau pathological conditions were not present in any of the US or Colombian\n                  <jats:italic>PSEN1<\/jats:italic>\n                  cases, and was seen in only 3% of the EOSADD cases. Significant large-vessel atherosclerosis was present in a much larger percentage of Colombian\n                  <jats:italic>PSEN1<\/jats:italic>\n                  cases, at almost 20% as compared to 0% and 3% of the US\n                  <jats:italic>PSEN1<\/jats:italic>\n                  and EOSADD cases, respectively. Small-vessel disease, or arteriolosclerosis, was much more common than large vessel disease, being present in all groups between 18% and 37%. Gross and microscopic infarcts, however, as well as gross or microscopic hemorrhages, were generally absent or present at very low percentages in all groups. White matter rarefaction (WMR) was remarkably common, at almost 60%, in the US\n                  <jats:italic>PSEN1<\/jats:italic>\n                  group, as compared to about 18% in the EOSADD cases, a significant difference. White matter rarefaction was not assessed in the Colombian\n                  <jats:italic>PSEN1<\/jats:italic>\n                  cases. The results presented here, as well as other evidence, indicates that LBD, TDP-43 pathology and WMR, as common comorbidities with autosomal dominant and early-onset sporadic ADD, should be considered when planning clinical trials with such subjects as they may increase variability in response rates. However, they may be at least partially dependent on ADNC and thus potentially addressable by anti-amyloid or and\/anti-tau therapies.\n                <\/jats:p>","DOI":"10.1101\/2023.08.14.23294081","type":"posted-content","created":{"date-parts":[[2023,8,17]],"date-time":"2023-08-17T12:11:04Z","timestamp":1692274264000},"source":"Crossref","is-referenced-by-count":5,"title":["Comorbidities in Early-Onset Sporadic versus Presenilin-1 Mutation-Associated Alzheimer\u2019s Disease Dementia: Evidence for Dependency on Alzheimer\u2019s Disease Neuropathological Changes"],"prefix":"10.64898","author":[{"given":"Diego","family":"Sepulveda-Falla","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos Andr\u00e9s","family":"Villegas Lanau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3870-2804","authenticated-orcid":false,"suffix":"III","given":"Charles","family":"White","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9527-2011","authenticated-orcid":false,"given":"Geidy E.","family":"Serrano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juliana","family":"Acosta-Uribe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Mej\u00eda-Cupajita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nelson David","family":"Villalba-Moreno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pinzhang","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Markus","family":"Glatzel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia K.","family":"Kofler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernardino","family":"Ghetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew P.","family":"Frosch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco","family":"Lopera Restrepo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth S.","family":"Kosik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas G.","family":"Beach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"54368","reference":[{"key":"2023082113150580000_2023.08.14.23294081v1.1","doi-asserted-by":"publisher","DOI":"10.1002\/ANA.25380"},{"key":"2023082113150580000_2023.08.14.23294081v1.2","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.neurobiolaging.2017.08.029","article-title":"Age and the association of dementia-related pathology with trajectories of cognitive decline","volume":"61","year":"2018","journal-title":"Neurobiol Aging"},{"key":"2023082113150580000_2023.08.14.23294081v1.3","doi-asserted-by":"crossref","first-page":"e0217566.","DOI":"10.1371\/journal.pone.0217566","article-title":"Faster cognitive decline in dementia due to Alzheimer disease with clinically undiagnosed Lewy body disease","volume":"14","year":"2019","journal-title":"PLoS One"},{"key":"2023082113150580000_2023.08.14.23294081v1.4","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1016\/j.mayocp.2017.02.011","article-title":"Alzheimer Disease: Scientific Breakthroughs and Translational Challenges","volume":"92","year":"2017","journal-title":"Mayo Clin Proc"},{"key":"2023082113150580000_2023.08.14.23294081v1.5","doi-asserted-by":"publisher","DOI":"10.1111\/neup.12189"},{"key":"2023082113150580000_2023.08.14.23294081v1.6","doi-asserted-by":"crossref","first-page":"389","DOI":"10.3233\/JAD-201213","article-title":"Alzheimer\u2019s disease neuropathological comorbidities are common in the younger-old","volume":"79","year":"2021","journal-title":"J Alzheimer\u2019s Dis"},{"key":"2023082113150580000_2023.08.14.23294081v1.7","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awab099"},{"key":"2023082113150580000_2023.08.14.23294081v1.8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3233\/JAD-2012-120907","article-title":"Phenotypic profile of early-onset familial Alzheimer\u2019s disease caused by presenilin-1 E280A mutation","volume":"32","year":"2012","journal-title":"J Alzheimer\u2019s Dis"},{"key":"2023082113150580000_2023.08.14.23294081v1.9","first-page":"112","article-title":"Biological and cognitive markers of presenilin1 E280A autosomal dominant Alzheimer\u2019s disease: a comprehensive review of the Colombian kindred","volume":"6","year":"2019","journal-title":"J Prev Alzheimers Dis"},{"key":"2023082113150580000_2023.08.14.23294081v1.10","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1093\/jnen\/nlv028","article-title":"Neuropathology of Autosomal Dominant Alzheimer Disease in the National Alzheimer Coordinating Center Database","volume":"75","year":"2016","journal-title":"J Neuropathol Exp Neurol"},{"key":"2023082113150580000_2023.08.14.23294081v1.11","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1097\/WAD.0000000000000279","article-title":"Version 3 of the National Alzheimer\u2019s Coordinating Center\u2019s Uniform Data Set","volume":"32","year":"2018","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"2023082113150580000_2023.08.14.23294081v1.12","doi-asserted-by":"publisher","DOI":"10.1093\/jnen\/nly049"},{"key":"2023082113150580000_2023.08.14.23294081v1.13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2011.10.007"},{"key":"2023082113150580000_2023.08.14.23294081v1.14","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-011-0910-3"},{"issue":"2","key":"2023082113150580000_2023.08.14.23294081v1.15","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s00401-020-02249-0","article-title":"A multifactorial model of pathology for age of onset heterogeneity in familial Alzheimer\u2019s disease","volume":"141","year":"2021","journal-title":"Acta Neuropathol"},{"key":"2023082113150580000_2023.08.14.23294081v1.16","doi-asserted-by":"crossref","first-page":"e13097","DOI":"10.1111\/bpa.13097","article-title":"Evidence of beta-amyloid independent small vessel disease in familial Alzheimer\u2019s disease","volume":"32","year":"2022","journal-title":"Brain Pathol"},{"key":"2023082113150580000_2023.08.14.23294081v1.17","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.58.12.1791"},{"key":"2023082113150580000_2023.08.14.23294081v1.18","doi-asserted-by":"publisher","DOI":"10.1111\/j.1750-3639.2008.00147.x"},{"key":"2023082113150580000_2023.08.14.23294081v1.19","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-006-0127-z"},{"key":"2023082113150580000_2023.08.14.23294081v1.20","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.41.4.479"},{"key":"2023082113150580000_2023.08.14.23294081v1.21","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/122.9.1709"},{"key":"2023082113150580000_2023.08.14.23294081v1.22","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1001\/jamaneurol.2014.681","article-title":"Clinical predictors of severe cerebral amyloid angiopathy and influence of APOE genotype in persons with pathologically verified Alzheimer disease","volume":"71","year":"2014","journal-title":"JAMA Neurol"},{"key":"2023082113150580000_2023.08.14.23294081v1.23","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.3233\/JAD-191023","article-title":"Association of hypercholesterolemia with Alzheimer\u2019s disease pathology and cerebral amyloid angiopathy","volume":"73","year":"2020","journal-title":"J Alzheimer\u2019s Dis"},{"key":"2023082113150580000_2023.08.14.23294081v1.24","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0054056"},{"key":"2023082113150580000_2023.08.14.23294081v1.25","doi-asserted-by":"publisher","DOI":"10.1038\/mp.2015.177"},{"key":"2023082113150580000_2023.08.14.23294081v1.26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2016.01.012"},{"key":"2023082113150580000_2023.08.14.23294081v1.27","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0611-3"},{"key":"2023082113150580000_2023.08.14.23294081v1.28","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-022-02467-8"},{"key":"2023082113150580000_2023.08.14.23294081v1.29","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s13024-023-00626-3","article-title":"Resistant and resilient mutations in protection against familial Alzheimer\u2019s disease: learning from nature","volume":"18","year":"2023","journal-title":"Mol Neurodegener"},{"key":"2023082113150580000_2023.08.14.23294081v1.30","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1038\/s41591-023-02318-3","article-title":"Resilience to autosomal dominant Alzheimer\u2019s disease in a Reelin-COLBOS heterozygous man","volume":"29","year":"2023","journal-title":"Nat Med"},{"key":"2023082113150580000_2023.08.14.23294081v1.31","doi-asserted-by":"crossref","unstructured":"Cochran JN , Acosta-Uribe J , Madrigal L , Aguill\u00f3n D , Garcia GP , Giraldo MM , Taylor JW , Bradley J , Fulton-Howard B , Andrews SJ , Acosta-Baena N , Alzate D , Garcia GP , Piedrahita F , Lopez HE , Anderson AG , Rodriguez-Nunez I , Roberts K , Absher D , Myers RM , Beecham GW , Reitz C , Rizzardi LF , Fernandez MV , Goate AM , Cruchaga C. Renton AE , Lopera F , Kosik KS (2020) Genetic Associations with Age at Dementia Onset in the PSEN1 E280A Colombian Kindred. medRxiv, doi: https:\/\/doi.org\/10.1101\/2020.09.23.20198424.","DOI":"10.1101\/2020.09.23.20198424"},{"key":"2023082113150580000_2023.08.14.23294081v1.32","doi-asserted-by":"publisher","DOI":"10.1016\/S0304-3940(97)00294-2"},{"key":"2023082113150580000_2023.08.14.23294081v1.33","doi-asserted-by":"publisher","DOI":"10.1002\/ana.20393"},{"key":"2023082113150580000_2023.08.14.23294081v1.34","doi-asserted-by":"publisher","DOI":"10.1007\/s004019900155"},{"key":"2023082113150580000_2023.08.14.23294081v1.35","doi-asserted-by":"publisher","DOI":"10.1016\/0304-3940(94)90666-1"},{"key":"2023082113150580000_2023.08.14.23294081v1.36","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9440(10)65722-7"},{"key":"2023082113150580000_2023.08.14.23294081v1.37","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.63.3.370"},{"key":"2023082113150580000_2023.08.14.23294081v1.38","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.4244-07.2007"},{"key":"2023082113150580000_2023.08.14.23294081v1.39","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/0197-4580(91)90007-7","article-title":"Gelsolin variant and beta-amyloid co-occur in a case of Alzheimer\u2019s with Lewy bodies","volume":"12","year":"1991","journal-title":"Neurobiol Aging"},{"key":"2023082113150580000_2023.08.14.23294081v1.40","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0029(20000701)50:1<10::AID-JEMT3>3.0.CO;2-6"},{"key":"2023082113150580000_2023.08.14.23294081v1.41","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1007\/s00702-018-1850-z","article-title":"Neuropathology and biochemistry of early onset familial Alzheimer\u2019s disease caused by presenilin-1 missense mutation Thr116Asn","volume":"125","year":"2018","journal-title":"J Neural Transm (Vienna)"},{"key":"2023082113150580000_2023.08.14.23294081v1.42","doi-asserted-by":"publisher","DOI":"10.1001\/archneurol.2009.277"},{"key":"2023082113150580000_2023.08.14.23294081v1.43","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1093\/brain\/awab434","article-title":"11C-PiB PET can underestimate brain amyloid-\u03b2 burden when cotton wool plaques are numerous","volume":"145","year":"2022","journal-title":"Brain"},{"key":"2023082113150580000_2023.08.14.23294081v1.44","doi-asserted-by":"crossref","first-page":"e1422","DOI":"10.1212\/WNL.0000000000200001","article-title":"Limbic-Predominant Age-Related TDP-43 Encephalopathy: Medical and Pathologic Factors Associated With Comorbid Hippocampal Sclerosis","volume":"98","year":"2022","journal-title":"Neurology"},{"key":"2023082113150580000_2023.08.14.23294081v1.45","doi-asserted-by":"crossref","first-page":"e12875","DOI":"10.1111\/nan.12875","article-title":"Arteriolar neuropathology in cerebral microvascular disease","volume":"49","year":"2023","journal-title":"Neuropathol Appl Neurobiol"},{"key":"2023082113150580000_2023.08.14.23294081v1.46","doi-asserted-by":"publisher","DOI":"10.1038\/emboj.2012.79"},{"key":"2023082113150580000_2023.08.14.23294081v1.47","first-page":"103","article-title":"Intracerebral hemorrhage in the oldest old: a population-based study (vantaa 85+)","volume":"3","year":"2012","journal-title":"Front Neurol"},{"key":"2023082113150580000_2023.08.14.23294081v1.48","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2012.10.011"},{"key":"2023082113150580000_2023.08.14.23294081v1.49","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s13195-022-01030-7","article-title":"White matter hyperintensities are a prominent feature of autosomal dominant Alzheimer\u2019s disease that emerge prior to dementia","volume":"14","year":"2022","journal-title":"Alzheimers Res Ther"},{"key":"2023082113150580000_2023.08.14.23294081v1.50","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awv048"},{"key":"2023082113150580000_2023.08.14.23294081v1.51","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410190306"},{"key":"2023082113150580000_2023.08.14.23294081v1.52","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/111.6.1425"},{"key":"2023082113150580000_2023.08.14.23294081v1.53","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.1991.00530220031015"},{"key":"2023082113150580000_2023.08.14.23294081v1.54","doi-asserted-by":"publisher","DOI":"10.1038\/nrneurol.2015.10"},{"key":"2023082113150580000_2023.08.14.23294081v1.55","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1111\/joim.12352","article-title":"White matter changes in familial Alzheimer\u2019s disease","volume":"278","year":"2015","journal-title":"J Intern Med"},{"key":"2023082113150580000_2023.08.14.23294081v1.56","first-page":"e12040","article-title":"Alzheimer-related altered white matter microstructural integrity in Down syndrome: A model for sporadic AD?","volume":"12","year":"2020","journal-title":"Alzheimers Dement (Amst)"},{"key":"2023082113150580000_2023.08.14.23294081v1.57","doi-asserted-by":"publisher","DOI":"10.1002\/ana.24647"},{"key":"2023082113150580000_2023.08.14.23294081v1.58","first-page":"187","article-title":"Subjects harboring presenilin familial Alzheimer\u2019s disease mutations exhibit diverse white matter biochemistry alterations","volume":"2","year":"2013","journal-title":"Am J Neurodegener Dis"},{"key":"2023082113150580000_2023.08.14.23294081v1.59","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-021-02376-2"},{"key":"2023082113150580000_2023.08.14.23294081v1.60","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00401-020-02235-6","article-title":"Brain arteriolosclerosis","volume":"141","year":"2021","journal-title":"Acta Neuropathol"},{"key":"2023082113150580000_2023.08.14.23294081v1.61","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1093\/jnen\/nlad026","article-title":"Cerebral white matter rarefaction has both neurodegenerative and vascular causes and may primarily be a distal axonopathy","volume":"82","year":"2023","journal-title":"J Neuropathol Exp Neurol"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1101\/2023.08.14.23294081","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T19:39:05Z","timestamp":1768505945000},"score":1,"resource":{"primary":{"URL":"http:\/\/medrxiv.org\/lookup\/doi\/10.1101\/2023.08.14.23294081"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,17]]},"references-count":61,"URL":"https:\/\/doi.org\/10.1101\/2023.08.14.23294081","relation":{},"subject":[],"published":{"date-parts":[[2023,8,17]]},"subtype":"preprint"}}